Biosante Pharmaceuticals Inc (NASDAQ:BPAX)

zzlangerhans (99.67) Submitted: 1/9/2012 8:13:27 PM : Start Price: $0.50 BPAX Score: +53.29

I'm still searching for that elusive CAPS multibagger, a quest which often causes me to hold my winners against my better judgement thereby losing everything I gained and more. Such was the case with BioSante, where I got in early and held my ground through a disastrous phase III data release. I expected the real battle of BioSante to come at the regulatory and commercialization level rather than the efficacy level, but so go my fortunes with binary catalysts.

I ditched an ugly losing score to refocus on the upcoming PDUFA for Bio-T-gel, postponed three months to February 14. It's hard to project much commercial success for yet another rub-on testosterone in a crowded market, but the drug is already partnered with Teva and stands a good chance of FDA approval. If it hadn't been for the Libigel smackdown, BioSante would probably be trading at a market cap over 100M just on the potential of Bio-T-gel. Hopefully I'll get the three bagger with BioSante that I missed the last time.